April 12, 2024
A Multicenter, Open-Label, Phase 2 Study of Intratumoral CMP-001 In Combination With An Intravenous PD-1-Blocking Antibody In Subjects With Selected Types of Advanced or Metastatic Cancer
Select an appointment date and time from available spots listed below.